Intra-arterial cold saline, minocycline, and magnesium for Ischemic Stroke
Phase-Based Progress Estimates
Effectiveness
Safety
North Shore University Hospital, Manhasset, NYIschemic StrokeIntra-arterial cold saline, minocycline, and magnesium - Drug
Study Summary
This trial is testing whether it is safe to give patients a cocktail of neuroprotective drugs immediately after they have a stroke, in order to try to improve long-term outcomes.
Eligible Conditions
- Ischemic Stroke
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: within 24 hours of treatment
24 hours after procedure
Infarct volume
90 days after intervention
Functional outcome
Hour 24
Intracranial hemorrhage
Hour 72
Presence of serious adverse event
Trial Safety
Safety Progress
Side Effects for
Armodafinil+Minocycline
20%Peripheral Neuropathy
Trial Design
1 Treatment Group
Intra-arterial neuroprotective substances
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: Intra-arterial cold saline, minocycline, and magnesium · No Placebo Group · Phase 1
Intra-arterial neuroprotective substances
Drug
Experimental Group · 1 Intervention: Intra-arterial cold saline, minocycline, and magnesium · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 24 hours of treatment
Who is running the clinical trial?
Northwell HealthLead Sponsor
426 Previous Clinical Trials
462,399 Total Patients Enrolled
1 Trials studying Ischemic Stroke
53 Patients Enrolled for Ischemic Stroke
Thomas W Link, MD, MSPrincipal InvestigatorNorthwell Health
Eligibility Criteria
Age 18 - 90 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: